Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545506 | 0.89 | CYP2A6 (0.61) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL30732355 | 0.86 | CYP1A2 (0.50) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL29152282 | 0.86 | CYP1A2 (0.50) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL7405579 | 0.84 | CYP1A2 (0.56) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL22922294 | 0.81 | CHRM2 (0.46) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL9267237 | 0.81 | NAPRT (0.46) | CHRNA7CYP2A6CYP1A2CYP2D6CYP2C19 | |
| Niacin SCHEMBL17633821 | 0.79 | ALDH1A1 (0.57) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL11177988 | 0.79 | CHRM2 (0.47) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL11179366 | 0.77 | CHRM2 (0.42) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL7545498 | 0.77 | CYP2D6 (0.46) | CHRNA7CYP1A2CYP2D6CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488544-B1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | UNIV MONASH (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8748582-B2 | Affinity ligands and methods for protein purification | MONASH UNIVERSITY (AU) | 2014-06-10 | — | — | US | disclosed |
| US-8748582-B2 | Affinity ligands and methods for protein purification | MONASH UNIVERSITY (AU) | 2014-06-10 | — | — | US | disclosed |
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MONASH UNIVERSITY | 2012-10-11 | — | — | US | disclosed |
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MONASH UNIVERSITY | 2012-10-11 | — | — | US | disclosed |
| WO-2011044637-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MONASH UNIVERSITY (AU) | 2011-04-21 | — | — | WO | disclosed |
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0199845-A1 | Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them | HEUMANN PHARMA GMBH & CO (DE) | 1986-11-05 | — | — | EP | disclosed |
| US-4551460-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-05 | — | — | US | disclosed |
| US-4499101-A | HISTAMINE H2-ANTAGONISTS; ANTISECRETORY ANTIINFLAMMOATORY AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-02-12 | — | — | US | disclosed |
| US-4271169-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-06-02 | — | — | US | disclosed |
| US-4233302-A | ANTIHISTAMINES, ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1980-11-11 | — | — | US | disclosed |
| US-4215125-A | H-2 HISTAMINE RECEPTOR INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-29 | — | — | US | disclosed |
| EP-0002930-A1 | Amine derivatives, their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1979-07-11 | — | — | EP | disclosed |
| US-4152443-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-01 | — | — | US | disclosed |
| US-4112104-A | UREA, THIOUREA OR GUANIDINE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-09-05 | — | — | US | disclosed |
| US-4080459-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-03-21 | — | — | US | disclosed |
| US-4067984-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-10 | — | — | US | disclosed |
| US-4025527-A | H-2 HISTAMINE RECEPTOR INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-24 | — | — | US | disclosed |
| US-4013769-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MAX, SPR, CCL2 | CHRNA7 1481/4885CYP2A6 4329/4885HRH1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.